Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 10, 2015 3:03pm
108 Views
Post# 24093666

RE:RE:Does PoC have a good side?

RE:RE:Does PoC have a good side?Still not pumping prince, just simple math to try to interpret the somewhat vague 250 MACE event target that RVX provided. Nowhere in your post do you show that my math was flawed. You may choose to believe or disbelieve the post-hoc RRR numbers and event rates, but they are what they are. Based on these, my math was sound and brought into question why they were intitally saying 2 years. Now, and only after today's webcast, do we have more clarity. So I have no problem revising my previous statements based upon today's new information, but I still stand by every single word I said before that was based on more limited available information. 

PoC wrote: "bearskinned, yoiur post is in fact not factual correct, as best i remember RVX has always been touting 2 years from start to end (dosing end), you chose to focus on MACE based on that post hoc analysis which i have always questioned the 77% RRR (i believe the 208 ARR but not the lipitor/crestor rate as being way too high (and ps i wonder if using only the stringest 3 criteria it is still the sam ARR))...and it is pumping when you come up with 6 months which is only 25 % of the two+ years RVX maintains or you pumped a 75% RRR R(relative runtime rate reduction) vs. RVX timeline (ROTLFMAO this is how hoity toity plays with stats)..and finally to help you get over yourself the trial will actually take as long as it takes so in finality no one will be right except largely by chance...and FYI the shareprice implication (which is why i invest) is hugely different 6 months vs. 2 years+ and i find it hard to believe you don't know that and the basis of "pump" relates to shareprice"
Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#XzqWCRYFSLuphdfo.99
Bullboard Posts